icon-folder.gif   Conference Reports for NATAP  
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
Integrated Resistance Analyses of HCV-Infected Patients Treated With Sofosbuvir, Velpatasvir, and Voxilaprevir for 8 and 12 Weeks From Phase 2 Studies
  Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Nancy Reau,1 Mindie H. Nguyen,2 Kris V. Kowdley,3 Edward J. Gane,4 Hadas Dvory-Sobol,5 Evguenia S. Svarovskaia,5
Jenny C. Yang,5 Luisa M. Stamm,5 Diana M. Brainard,5 Michael D. Miller,5 Hongmei Mo,5 Eric Lawitz,6 Paul Y. Kwo,7 Michael P. Curry,8 Ira M. Jacobson9
1Rush University Medical Center, Chicago, IL; 2Stanford Medicine, Stanford, CA; 3Swedish Medical Center, Seattle, WA; 4Auckland City Hospital, New Zealand Liver Transplant Unit, Auckland, New Zealand;
5Gilead Sciences, Inc., Foster City, CA; 6The University of Texas Health Science Center at San Antonio, Texas Liver Institute, San Antonio; 7Indiana University School of Medicine, Indianapolis, IN; 8Beth Israel Deaconess Medical Center, Boston, MA; 9Mount Sinai Beth Israel, New York, NY









1. Jacobson IM, et al. N Engl J Med 2013;368:1867-77; 2. Lawitz E, et al. N Engl J Med 2013;368:1878-87; 3. Cheng G, et al. EASL 2013, poster 1191; 4. German P, et al. EASL 2013, poster 1195; 5. Lawitz E, et al. J Viral Hepat 2015;22:1011-9; 6. Taylor JG, et al. EASL 2015, poster 899; 7. Kirby B, et al. EASL 2015, poster 861; 8. Rodriguez-Torres M, et al. J Viral Hepat 2016 [ePub]. 9. Gane EJ, et al. EASL 2016, poster SAT-138; 10. Lawitz E, et al. EASL 2016, abstr PS008; 11. Lawitz E, et al. EASL 2016, oral: Parallel Session: HCV I.